In late 2025, SELLAS Life Sciences Group reported encouraging Phase 2 data for SLS009 in combination with azacitidine and venetoclax in relapsed or refractory acute myeloid leukemia and confirmed that ...

Kura Oncology’s latest earnings call struck an upbeat tone, as management spotlighted a swift U.S. launch for newly approved Comzifty, strong payer traction, and a deep pipeline of upcoming clinical ...

The debate centers on Sellas’ Phase 3 Regal trial, which is testing its immunotherapy Galinpepimut-S (GPS) as a maintenance ...

Fred Hutch Cancer Center hematologists took center stage at the 2026 Tandem Meetings, a multidisciplinary meeting of experts in the field of blood stem cell transplantation, held in Salt Lake City ...

Treatments for Alzheimer disease agitation, focal segmental glomerulosclerosis, hematological malignancies, HIV-1, and obesity are under review.

Barclays cut the price target on Blackstone Inc. (NYSE:BX) to $126 from $164 on March 2, maintaining an Equal Weight rating on the shares while revising estimates across the alter ...

The CEO said Sellas is pursuing a “security force” immunotherapy strategy that trains immune cells to recognize cancer even ...

CD25 rewires oncogene signaling in AML and ALL, revealing druggable complexes and a bold strategy: push pathways into toxic ...

A Falls Church City family’s battle with leukemia and a daughter’s determination to help others facing the disease will be at ...

Acute myeloid leukemia, often called AML, is one of the most aggressive forms of blood cancer. It develops in the bone marrow, the soft tissue inside bones where blood cells are made. In healthy ...

Investigators at CHOP and UPenn found that lower cell counts could still be associated with poor outcomes if the cells were poorly differentiated.

My grandpa dead was a blessing shadowed by the pain he was forced to endure because our state laws refused to give him ...